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summARy - ovarian hyperstimulation syndrome is the most dangerous complication fo-
llowing the administration of gonadotropins. There is no preventive and pharmacological interventi-
on that can fully prevent development of this syndrome. The best strategy to reduce the incidence of 
the condition is to identify the patients at risk before ovarian stimulation and to recognize potential 
predictors. A history of ovarian hyperstimulation is an important risk factor for recurrence of the 
syndrome. The risk of the syndrome is evident with elevated gonadotropin dosages and with the use 
of gonadotropin releasing hormone agonists. human chorionic gonadotropin is the main risk factor. 
The combination of pretreatment diagnosis of polycystic ovary disease and estradiol of 4500 pg/
ml gives higher prediction rates for the risk factor. serum concentration of inhibin is not a reliable 
predictor of the syndrome. Recent evaluation of antimüllerian hormone as a reliable predictor can-
didate, vascular endothelial growth factor with cadherin as indicators of vascular permeability, and 
detection of mutations in the follicular stimulating hormone receptor as predictors of severity offer 
new insights in the prognosis of the syndrome. identification of these prognostic markers in patients 
at risk would be very useful for prevention of the syndrome prior to the appearance of symptoms. 
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Introduction
ovarian hyperstimulation syndrome (ohss) is 
the most serious and potentially lethal complication 
of controlled ovarian hyperstimulation (Coh) in the 
treatment of infertility1. it is a typically iatrogenic 
complication of ovulation induction associated with 
the use of exogenous gonadotropins and aggressive 
Coh or occasionally with clomiphene citrate, oc-
curring during the luteal phase or early pregnancy. 
however, some forms of ohss invariably reported 
during pregnancy may be extremely rarely associated 
with a spontaneous ovulatory cycle, usually in case of 
multiple gestations, hydatid mole, hypothyroidism, 
polycystic ovary syndrome (pCos), and follicle-stim-
ulating hormone receptor (fshr) mutations2. 
The incidence of ohss has not changed over years, 
and it might not change until the pathogenesis is com-
pletely understood. severe forms of ohss arise in 
0.5%-5% of in vitro fertilization (ivf) cycles. A criti-
cal condition develops with massive ascites or pleural 
effusion, dyspnea, hemoconcentration and oliguria3. 
The principal pathology is an increase in capillary per-
meability of the ovaries and mesothelial surfaces with 
extravasation of protein-rich fluid into the third space, 
which in turn causes hypovolemia, reduced organ perfu-
sion and the risk of thromboembolism. The manifesta-
tions of ohss are believed to be the result of increased 
capillary permeability and range from mild abdominal 
discomfort to severe, life-threatening illness4. 
The pathogenesis of ohss is a complex process, 
which still remains unclear. it was assumed that cer-
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tain ovarian biosynthetic components produced in ex-
cess during the induction of ovulation initiate the cas-
cade of events that result in the syndrome. in recent 
years, several studies indicate that human chorionic 
gonadotropin (hCg), either exogenous or endogenous 
(e.g., pregnancy derived), is the main factor that trig-
gers ohss. it seems to be the pivotal stimulus of the 
syndrome in a susceptible woman because elimination 
of hCg will prevent the full-blown picture of the syn-
drome5,6. using an in vivo murine model to induce 
ohss, it was clearly demonstrated that vascular en-
dothelial growth factor (vegf) and vegf-2 recep-
tors are produced in human granulosa-lutein cells and 
that vegf acts through its receptors to increase vas-
cular permeability in response to hCg. vegf is the 
main responsible mediator because of the prominent 
role in the pathologic increase of vascular permeabili-
ty. in addition, hCg and vegf individually produce 
a significant increase in ve-cadherin release, which is 
involved in the loosening of endothelial intercellular 
junctions. ve-cadherin is a soluble cell adhesion mol-
ecule, which may play a key role in the pathophysiol-
ogy and progression of vascular hyperpermeability6-8.
Currently, the condition of ohss is incompletely 
understood and its pathogenesis remains complex. 
There is no pharmacological intervention that fully 
prevents development of the syndrome and no com-
pletely curative therapy. withholding hCg and cycle 
cancellation was the most commonly used method of 
preventing ohss, but at the expense of losing the 
cycle, with large psychological and financial burdens 
imposed onto the patient9. Coasting with cessation 
of gonadotropins has been widely adopted to reduce 
ohss, however, prolonged coasting has a drawback 
of a reduced pregnancy rate10. in the first report, early 
unilateral follicular aspiration applied in patients at 
risk of ohss 12 h after hCg administration was fol-
lowed by regular oocyte retrieval 36 h later. The meth-
od of post-hCg aspiration in one ovary has been de-
scribed as a simple and effective method that prevents 
the development of ohss11. however, in a prospec-
tive randomized study comparing unilateral ovarian 
aspiration with coasting, neither method completely 
prevented the occurrence of severe ohss12. pro-
phylactic albumin could be helpful in preventing it 
in high risk patients. however, it does not eliminate 
severe ohss completely9. Cryopreservation of all 
embryos for postponement of transfer can prevent the 
occurrence of late ohss from pregnancy. in high risk 
patients, mild ovarian stimulation with the gonado-
tropin-releasing hormone (gnRh) antagonist protocol 
may prevent ohss9,13. The vast majority of patients 
with severe ohss had their condition successfully 
managed as outpatients with the use of aggressive 
transvaginal paracentesis14. it was recently found that 
dopamine or dopamine receptor 2 agonists transact 
inhibition of vegf-2 receptors dependent vascular 
permeability through its endothelial cell receptors6. 
ohss continues to be among the most serious 
complications of ovulation induction with exogenous 
gonadotropins. All physicians who prescribe medi-
cations with the potential to cause ohss require 
knowledge of the pathophysiological mechanisms 
of the disease and experience with ovulation induc-
tion therapy, prevention strategies, staging and treat-
ment1,15. As in the prevention of any disease, it should 
be emphasized that the possibility of primary preven-
tion depends on two main requirements, i.e. the etiol-
ogy of the disease that must be known, while causal 
and predisposing factors should be identified. it must 
be feasible to avoid or manipulate such factors as part 
of prevention. At present, the greatest clinical chal-
lenge is to correctly predict patients at a high risk of 
ohss, and how to treat them to prevent the compli-
cation. The best strategy and the key to prevent ohss 
or to reduce its incidence to minimum is to identify 
patients at risk before ovarian stimulation and to rec-
ognize some prognostic markers that may be benefi-
cial in predicting ohss development. 
Risk Factors
History of OHSS
Those patients with pCos who developed ohss 
in a previous cycle are prone to develop the condition 
in any subsequent cycle. in future cycles, extreme cau-
tion should be taken and it is suggested that the lowest 
possible dose of fsh be given as a starting point16. in 
addition, patients should be closely monitored using 
ultrasound and serial estradiol (e2) measurements as 
a preventive measure in patients at risk of develop-
ing ohss. The use of recombinant fsh (rfsh) in 
a low-dose protocol was effective in achieving a 20% 
pregnancy rate without ohss17.
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Age
it has been reported in most studies that women 
suffering from ohss were significantly younger than 
those who did not. A plausible explanation is that the 
ovaries of younger women are more responsive to go-
nadotropins because they possess a higher density of 
gonadotropin receptors or a larger number of follicles 
that are able to respond to gonadotropins15,18.
Body mass index (BMI)
only one group with 54 ohss cycles has de-
scribed positive correlation between lean body mass 
and ohss19. however, others failed to find correla-
tion between either body mass index (Bmi) or body 
weight and propensity of ohss15,18. Bmi does not 
appear to be a useful marker of an increased risk of 
ohss.
Allergy
The pathophysiological changes that occur in the 
ovaries during ohss closely resemble an overactive 
inflammatory response with participation of immu-
nomodulatory cytokines. it has been hypothesized 
that differences in the immune sensitivity of patients 
may be a predictive sign of ohss. in a prospective 
study recording 18 severe ohss cases, a significant 
increase was observed in the prevalence of allergies 
(50% versus 21% in the control group)18. however, this 
observation should be studied through biological as-
sessment in a larger cohort.
PCOS
it is well established that pCos is more frequent 
in patients with ohss and appears to be the ma-
jor predisposing factor in a large number of studies. 
women with pCos appear to have greater sensitiv-
ity to gonadotropins and this effect may be second-
ary to the increased recruitment of follicles of varying 
maturational phases owing to pathologic endogenous 
gonadotropin and steroid hormone responses to ex-
ogenous stimulation9,15,20. increased ovarian volume 
together with increased number of antral follicles and 
the „necklace“ or „ring of pearls“ appearance of the 
ovaries should alert the clinician to a higher sensi-
tivity to gonadotropins. in addition, significant cor-
relation was found between the baseline number of 
follicles and the number of oocytes retrieved in 101 
patients who underwent ivf21. The levels of inhibin B 
are high in pCos patients and the expression pattern 
of inhibin in the ovary suggests that inhibin has roles 
in the regulation of both steroidogenesis and growth 
during follicle recruitment22. it was demonstrated 
that hyperinsulinemic pCos patients are exposed to 
a greater risk than normoinsulinemic patients are. The 
mechanism may be related to that as insulin acts as a 
survival factor for early stage follicles and this would 
allow for more follicles to mature into a luteinizing 
hormone (lh) and hCg-responsive state23. An in-
creased expression of vegf may be related to the in-
creased vascularity within the hyperthecal stroma of 
women with pCos, and this may be responsible for 
their higher risk of ohss24. Therefore, it is impor-
tant to diagnose pCos before ovarian stimulation is 
initiated, as these patients are more likely do develop 
severe ohss. There is evidence that severe ohss 
is preventable in patients with pCos when ovarian 
stimulation is achieved with a chronic low-dose go-
nadotropin protocol, compared with a conventional 
regimen20.
Antimüllerian hormone (AMH)
The traditional determinants for ohss prior to 
gonadotropin stimulation appear to include only the 
subject’s age, lean habitus and signs of pCos (both 
hormonal and ultrasonographic characteristics). Ac-
curate prediction of ohss in an individual ivf 
treatment cycle, however, remains a difficult task. se-
rum levels of Amh have been reported recently to 
be closely related to the ovarian response or ovarian 
reserve during ivf cycles25. The serum level of Amh 
would appear to better reflect the level of ovarian ag-
ing than other known markers of ovarian reserve, such 
as basal serum fsh level, inhibin B and antral follicle 
count. in a recently reported study, all patients with 
cancelled ivf cycles due to poor response to Cos 
were in the group with the lowest serum Amh level, 
whereas those with cancelled cycles due to a high risk 
of ohss had serum levels in the highest quartile26. 
Based on this evidence, Amh may be a useful marker 
to predict ohss for ivf cycles in addition to be-
ing an appropriate marker of ovarian reserve. fur-
thermore, in women with pCos, serum Amh level 
appeared to be strongly elevated and to be associated 
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significantly with ultrasonographic features of pCos, 
such as the presence of multiple small follicles in the 
ovaries. The inverse relationship between Amh and 
e2 levels suggests that Amh may modulate ovarian 
e2 synthesis and have a role in the disordered follicu-
logenesis characteristic of pCos27. The Amh level 
has been reported to affect the initial recruitment of 
primordial follicles and the cyclic recruitment of fsh 
dependent follicles (follicular sensitivity to fsh). se-
rum level of Amh may precisely reflect the number 
of small to intermediate follicles and they correlate 
strongly with the number of small antral follicles 
present (diameter <12 mm)28. A recent retrospective 
study showed that the mean follicular phase Amh 
level was 3.62 ng/ml and was about 6-fold higher in 
patients who subsequently developed ohss than in 
non-hyperstimulated ones29. moreover, these results 
were later confirmed in a cohort of 262 ivf cycles in-
vestigated prospectively, and the mean serum Amh 
level of 5.02 ng/ml has been reported in ohss pa-
tients. The basal serum Amh level is reported to be 
a reliable marker of ovarian response to ovulation in-
duction and a significant predictor of ohss, better 
than age or Bmi. Currently, it could be utilized ef-
fectively as a prognostic marker to predict ohss and 
thus to direct the selection of mild Coh protocols30.
Stimulation protocols
There is no doubt that the incidence of ohss is 
related to the stimulation regimen used. The risk of 
ohss is particularly evident when Coh for ivf 
procedure is performed with elevated gonadotropin 
dosages31. it is advisable to use a low starting dose of 
150 iu for all patients at the possible risk of ohss, 
irrespective of their age. The low-dose, step-up proto-
col and the step-down protocol are associated with a 
low risk of ohss. A much higher incidence of ohss 
has been observed when using urinary gonadotro-
pins than with purified fsh in clomiphene-resistant 
pCos32. The use of gonadotropin releasing hormone 
(gnRh) agonists, especially of a long protocol, in-
creases the incidence of ohss, maybe because of 
the stimulation of a large cohort of follicles associ-
ated with the abolition of the spontaneous luteiniza-
tion process1,9,15. hCg is currently used as a standard 
method for triggering oocyte maturation, but it is the 
main factor that increases the risk of ohss. There-
fore, it has been suggested that a lower dose of urinary 
hCg (e.g., 5000 vs. standard 10,000 iu dosage) be 
used for ovulation induction in the presence of risk 
factors of ohss1. Alternatively, a gnRh agonist or 
recombinant lh might be used to promote final oo-
cyte maturation and induce ovulation33. Regardless 
of whether hCg or its alternatives are administered 
at midcycle, the use of progesterone for luteal phase 
support rather than supplemental doses of hCg may 
further reduce the risk of ohss34. 
Response to ovulation stimulation
Although the mean e2 levels are almost always 
significantly higher following Coh and hCg in pa-
tients who develop ohss compared with controls, 
the relevance of e2 levels has been challenged because 
severe ohss has been observed in patients with very 
low e2 levels of 475 and 29 pg/ml30,35. The threshold 
of e2 peak level above which there is a considerably 
higher risk of ohss, varies widely among different 
investigators and most of the studies selected e2 of 
3000 pg/ml as a safe value for hCg administration. 
monitoring e2 was found to be effective in reducing 
the incidence of ohss. it is suggested that the asso-
ciation of a high e2 level with ohss is a mere marker 
of granulosa cell activity. Although e2 alone is not a 
sufficiently predictive factor, there is a general opin-
ion that e2 assay is an important marker to detect the 
majority of patients at risk of ohss36.
The growing follicular count is correlated with the 
ohss status, since the high number of growing fol-
licles is a prerequisite for ohss development. The 
risk of ohss was found to be often related to the 
large number or size of pre-ovulatory follicles on the 
day of hCg administration and to the number of col-
lected oocytes (90% of follicles seen)18. As individual 
markers, each of these factors together with e2 peak 
value and the presence of pCos show a suboptimal 
sensitivity to predict ohss development. however, 
the combination of pretreatment diagnosis of pCos 
along with a threshold of more than 15-18 follicles 
>15 mm in size and e2 of 4500 pg/ml gives higher 
prediction rates for the risk of developing ohss37,38. 
it was observed previously that basal levels of in-
hibin B on day 3 and day 5 positively correlated with 
the expected ovarian response and ivf outcome39. 
however, analyzing serum and follicular levels of in-
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hibin A and inhibin B following regular Coh at the 
time of oocyte pickup, it was found that both serum 
inhibin A and inhibin B were elevated at ohss on-
set, but that only inhibin A was elevated significantly. 
moreover, serum concentrations of inhibin A and 
inhibin B strongly correlated with the growing fol-
licular count. Considering these observations, it was 
concluded that serum concentration of inhibin is not a 
very reliable predictor of ohss40.
vegf is the most important mediator of hCg-
dependent increased ovarian angiogenesis. The ex-
pression of vegf and vegf-2 receptors increases 
during ovarian stimulation with gonadotropins and 
with the administration of hCg the expression of 
each rises to maximum. The expression of vegf/
vegf-2 mRNAs correlates with stimulation of new 
blood vessel development, but also induces vascular 
hyperpermeability, with both peaking 48 h follow-
ing hCg6. Recent observations suggest that increased 
vascular permeability may be mediated through ad-
hesion molecules such as ve-cadherin, a component 
of the adherence junction strand and the endothelial 
barrier. it was reported that women with severe ohss 
had significantly higher levels of ve-cadherin than 
patients without ohss. serum ve-cadherin levels 
decreased with clinical improvement; however, they 
did not reach normal values in the resolution phase. 
serum ve-cadherin levels were more closely chrono-
logically correlated with corpus luteum function than 
with biological and clinical aspects of severe ohss. 
ve-cadherin may be involved in the pathogenesis of 
severe ohss and may possibly serve as an indicator of 
corpus luteum function after Coh, which indirectly 
reflects the risk of ohss development7,41. 
several gene variations in the fshr gene have been 
identified in the very rare cases of spontaneous ohss. 
There are only few published data on gene variations 
in sterility and iatrogenic ohss. in most cases, acti-
vation of the fshr gene causes ovarian hyper-respon-
siveness to circulating fsh or even cross-responsive-
ness of fshr to hCg or thyroid-stimulating hormone 
(tsh), leading to predisposition to ohss. however, 
mutations in the fshr could be inactivated by reduc-
ing the fshr function up to a total block, resulting 
in amenorrhea, infertility and primary ovarian failure. 
polymorphisms of fshr have been investigated and to 
date 744 single nucleotide polymorphisms have been 
identified in the fshr gene, of which only eight are 
located in the coding region, exons, with the rest be-
ing intronic. interestingly, a significant enrichment in 
the allele N680 was observed as the severity of ohss 
increased. it was demonstrated that identification of 
the polymorphism of fshr, ser680Asn, in the fshr 
gene could not identify patients that would develop 
ohss, but could predict the severity of symptoms 
among iatrogenic ohss patients41-43. 
Conclusion 
until the multifactorial etiopathogenesis of ohss 
is completely understood, absolute prevention will not 
be possible. At present, treatment of the acute phase of 
ohss merely relies on an empirical and symptomatic 
approach. more appropriate methods would require 
better understanding of the underlying pathophysi-
ological mechanisms to promote an etiologic thera-
peutic approach. it seems reasonable that identifica-
tion of risk factors and potential prognostic markers 
in patients at a high risk of ohss could be very use-
ful in prevention of complications prior to ovulation 
induction. As previously described, pCos, elevated 
gonadotropin and hCg dosages, gnRh agonists and 
combination of increased e2 peak levels with larger 
number of follicle represent important risk factors of 
threatening ohss. moreover, recent evaluation of 
Amh as a reliable predictor candidate and the po-
tential roles of vegf, ve-cadherin and fshr mu-
tations as prognostic markers represent new insights 
in the prognosis of ohss. The presence of these risk 
factors and predictors need to alert all clinicians to be 
prepared to recognize and to prevent the condition, 
enabling the use of low-dose protocols with gonado-
tropins and hCg dose tapering or its alternatives, be-
fore the appearance of signs of severe ohss. 
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ovarijski stimulacijski sindrom je najopasnija komplikacija nakon primjene gonadotropina. Ne postoji nijedna preven-
tivna ni farmakološka intervencija koja u potpunosti sprječava pojavu ovoga sindroma. Najbolja strategija koja smanjuje 
pojavnost takvog stanja je identifikacija rizičnih bolesnica prije stimulacije ovulacije te prepoznavanje mogućih predznaka 
bolesti. Anamnestički podatak o ranijoj hiperstimulaciji jajnika predstavlja važan rizični čimbenik za ponovno javljanje 
sindroma. Rizičnost za nastanak sindroma je očita pri korištenju gonadotropina u većim dozama, kao i kod primjene 
agonista gonadotropnog otpuštajućeg hormona. humani korionski gonadotropin je glavni rizični čimbenik. Kombinacija 
prethodno utvrđene dijagnoze policističnih ovarija te koncentracija estradiola iznad 4500 pg/ml omogućuju bolje pred-
skazivanje čimbenika rizičnosti. Koncentracija inhibina u serumu nije pouzdana u predikciji sindroma. Nedavne spoznaje 
o antimilerovom hormonu kao pouzdanom kandidatu u predskazivanju sindroma, vaskularnom faktoru rasta s kaderinom 
kao pokazateljima vaskularne propusnosti te otkriće mutacija receptora folikularno stimulirajućeg hormona koji ukazuju 
na težinu bolesti predstavljaju nove uvide u prognozi ovoga sindroma. prepoznavanje ovih prognostičkih biljega u rizičnoj 
skupini bolesnica bilo bi vrlo korisno u prevenciji sindroma prije pojave simptoma bolesti.
Ključne riječi: Sindrom hiperstimulacije jajnika; Indukcija ovulacije – nuspojave; Čimbenici rizika; Prediktivna vrijednost 
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